Eribulin is known generically as eribulin mesylate and is an injection. The usual dose administered is (in a 21-day course): 1.4 mg/m2 given on days 1 and 8. Erizibulin mesylate, currently available only as an injection (shot), is indicated for the treatment of patients with metastatic breast cancer who have been treated with at least 2 chemotherapy regimens. Erizibulin mesylate is dissolved in 5% ethanol aqueous solution by volume at a concentration of 0.5 g/mL, and is administered as a 21-day course of 1.4 mg/m2 on days 1 and 8, respectively, as an intravenous injection over 2 to 5 minutes. It is important to note that the contraindications to eribulin mesylate are unclear. Common adverse reactions are neutropenia and leukopenia, while perceptible adverse reactions include nausea, malaise, and diarrhea. Erizibulin Mesylate should be administered by a healthcare professional.